Read Larry Connors' blog – Short Term Trading Strategies
The reported bottom line result was 23.3 per cent down on the net profit of $84.0 million in the prior year.
But net profit after tax from continuing operations, before non-recurring items, was $74.9 million, up 14 per cent on the prior year.
"We have had a good start to full year 2009, with the hospitals experiencing strong demand and the pathology group building on the significant growth of the second half of full year 2008," Healthscope said.
"It is not expected that the changes to the Medicare surcharge levy threshold level announced in the federal budget will impact earnings in the next period, with underlying volume growth in hospitals remaining strong, and health fund agreements in place with most major health funds for terms to run varying from one to three years."
The company said it would provide further guidance at its annual general meeting in October.
Healthscope declared a final dividend of ten cents per share, bringing the total dividend for the year to 19.5 cents, compared to a total of 17.5 cents in 2007.
Revenue rose 16.3 per cent to $1.49 billion.
Non-recurring items reduced the group result by $10.4 million.
The non-recurring items primarily related to costs incurred in Healthscope's failed attempt to take over Symbion Health, which was successfully acquired by Primary Health Care Ltd.
The prior year's result had been boosted by a $15.1 million gain on the sale of some hospitals and a $2.9 million contribution from divested hospitals.
Healthscope said strong revenue growth, improved margins in core hospitals, contributions from acquisitions and improved performance of the pathology group in the second half contributed to the higher underlying result.
Earnings before interest, tax, depreciation and amortisation (EBITDA) from continuing operations rose 15 per cent to $197.9 million.
The company said core hospitals and hospitals acquired during the 2007 year had generated strong revenue and margin improvement.
Domestic pathology showed solid revenue and earnings growth despite market share losses in Western Australia.
Offshore pathology operations were performing well, especially in Malaysia and Singapore.
EBITDA from continuing operations in the hospitals division rose 14.4 per cent to $156.5 million, and EBITDA in pathology for 2008 was $51.2 million.
(AAP)
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403
© Copyright 2009 The Connors Group, Inc.
